A Phase 1-2 Study of Ti-061 Alone and in combination with other anti-cancer agents in Patients with Advanced Malignancies

Trial Profile

A Phase 1-2 Study of Ti-061 Alone and in combination with other anti-cancer agents in Patients with Advanced Malignancies

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 03 Oct 2017

At a glance

  • Drugs TI 061 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Tioma Therapeutics
  • Most Recent Events

    • 03 Oct 2017 Status changed from recruiting to discontinued.
    • 16 Jun 2017 New trial record
    • 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top